Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease
Objective: To assess influences of dopamine deficiency on the causal interplay within the motor network during bimanual finger tapping in Parkinson's disease (PD) patients. Background:…Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión
Objective: This study main objective is to prospectively report the 10-year incidence of polineuropathy in Parkinson´s disease patients from southern Spain treated with LCIG. Background: Patients with…Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study
Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.
Objective: To better delineate risk profiles for the development of levodopa-induced dyskinesia is an important effort that can help understand this phenomenon and could impact…The SYNAPSES study (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey
Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience
Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in Parkinson’s disease (PD) patients. Background: LID are…Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.
Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 62
- Next Page »